Compliance with ICH stability requirements is a necessary step in getting your new drugs approved. Yet drugmakers routinely give it short shrift — to their sorrow.
Failure to comply can trigger an FDA deficiency letter ... resulting in shortened shelf lives ... and worst of all, delay the new drug approval (NDA) process.
But compliance is complex, and the rules often vary from country to country and regulator to regulator. It’s about time someone simplified things.
And someone has.
Register now for an all-new FDAnews webinar that teaches you what you need to know ... in a mere 90 minutes.
Participating from the convenience of your desktop, you’ll cover everything from the basics — what ICH Q1A(R2)-Q1F says, and what it actually means — to tailoring a compliance routine to fit your specific products. You’ll learn:
The requirements for ICH stability studies ...
The requirements for analytical methods ...
How to interpret data generated by the stability programs ...
How to design the right stability programs for your particular drugs ...
And much more!
Ph.D. biochemist Wayland Rushing Ph.D., Director of Scientific Affairs, EAG Labs, will be your guide. Dr. Rushing’s deep background in CMC program design and related topics makes him the right expert for the job.
The NDA process is too important to take chances with. Don’t risk missteps that could cost your organization perhaps millions of dollars in lost opportunity. Sign up today.